• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

VE-钙黏蛋白/β-连环蛋白信号轴调节免疫细胞浸润肿瘤。

The VE-Cadherin/β-catenin signalling axis regulates immune cell infiltration into tumours.

机构信息

Centre for the Endothelium, Vascular Biology Program, Centenary Institute, The University of Sydney, Sydney, 2050, Australia.

Liver Injury and Cancer Program, Centenary Institute, The University of Sydney, Sydney, 2050, Australia.

出版信息

Cancer Lett. 2021 Jan 1;496:1-15. doi: 10.1016/j.canlet.2020.09.026. Epub 2020 Sep 28.

DOI:10.1016/j.canlet.2020.09.026
PMID:32991950
Abstract

Vascular normalisation, the process that reverses the structural and functional abnormalities seen in tumour-associated vessels, is also accompanied by changes in leucocyte trafficking. Our previous studies have shown the normalisation effects of the agent CD5-2 which acts to stabilise VE-Cadherin leading to increased penetration of CD8 T cells but decreased infiltration of neutrophils (CD11bGr1) into tumour parenchyma. In the present study, we demonstrate that VE-Cadherin stabilisation through CD5-2 treatment of purified endothelial cells (ECs) results in a similar leucocyte-selective regulation of transmigration, suggesting the existence of an endothelial specific intrinsic mechanism. Further, we show by RNA sequencing (RNA-seq)-based transcriptomic analysis, that treatment of ECs with CD5-2 regulates chemokines known to be involved in leucocyte transmigration, including upregulation of CCL2 and CXCL10 that facilitate CD8 T cell transmigration. Both in vitro and in vivo mechanistic studies revealed that the increased CCL2 expression was dependent on expression of VE-Cadherin and downstream activation of the AKT/GSK3β/β-catenin/TCF4 signalling pathway. CD5-2 treatment also contributed to the reorganisation of the cytoskeleton, inducing reorganisation of stress fibres to circumferential actin, which previously has been described as associated with the stabilisation of the endothelial barrier, and amplification of the transcellular migration of CD8 T cells. Thus, we propose that promotion of endothelial junctional integrity during vascular normalisation not only inhibits vascular leak but also resets the endothelial dependent regulation of immune cell infiltration.

摘要

血管正常化是指逆转肿瘤相关血管中结构和功能异常的过程,同时伴随着白细胞迁移的变化。我们之前的研究表明,CD5-2 药物具有正常化作用,它可以稳定 VE-钙黏蛋白,从而增加 CD8 T 细胞的穿透性,但减少中性粒细胞(CD11bGr1)浸润肿瘤实质。在本研究中,我们证明通过 CD5-2 处理纯化的内皮细胞(ECs)稳定 VE-钙黏蛋白,导致白细胞迁移的类似选择性调节,这表明存在内皮细胞特异性内在机制。此外,我们通过基于 RNA 测序(RNA-seq)的转录组分析表明,CD5-2 处理 ECs 可调节已知参与白细胞迁移的趋化因子,包括上调 CCL2 和 CXCL10,促进 CD8 T 细胞迁移。体内外机制研究表明,CCL2 表达的增加依赖于 VE-钙黏蛋白的表达和 AKT/GSK3β/β-catenin/TCF4 信号通路的下游激活。CD5-2 处理还导致细胞骨架的重新组织,诱导应激纤维向周向肌动蛋白的重新组织,这以前被描述为与内皮屏障的稳定和 CD8 T 细胞的跨细胞迁移的放大有关。因此,我们提出,在血管正常化过程中促进内皮连接完整性不仅抑制血管渗漏,而且重置内皮对免疫细胞浸润的调节。

相似文献

1
The VE-Cadherin/β-catenin signalling axis regulates immune cell infiltration into tumours.VE-钙黏蛋白/β-连环蛋白信号轴调节免疫细胞浸润肿瘤。
Cancer Lett. 2021 Jan 1;496:1-15. doi: 10.1016/j.canlet.2020.09.026. Epub 2020 Sep 28.
2
VE-PTP maintains the endothelial barrier via plakoglobin and becomes dissociated from VE-cadherin by leukocytes and by VEGF.血管内皮蛋白酪氨酸磷酸酶(VE-PTP)通过桥粒珠蛋白维持内皮屏障,并被白细胞和血管内皮生长因子(VEGF)从血管内皮钙黏蛋白上解离下来。
J Exp Med. 2008 Nov 24;205(12):2929-45. doi: 10.1084/jem.20080406. Epub 2008 Nov 17.
3
Targeting Vascular Endothelial-Cadherin in Tumor-Associated Blood Vessels Promotes T-cell-Mediated Immunotherapy.靶向肿瘤相关血管中的血管内皮钙黏蛋白促进 T 细胞介导的免疫治疗。
Cancer Res. 2017 Aug 15;77(16):4434-4447. doi: 10.1158/0008-5472.CAN-16-3129. Epub 2017 Jun 27.
4
hnRNPA2/B1 Ameliorates LPS-Induced Endothelial Injury through NF-B Pathway and VE-Cadherin/-Catenin Signaling Modulation In Vitro.hnRNPA2/B1 通过调控 NF-κB 通路和 VE-钙黏蛋白/连环蛋白信号转导减轻 LPS 诱导的内皮细胞损伤。
Mediators Inflamm. 2020 May 30;2020:6458791. doi: 10.1155/2020/6458791. eCollection 2020.
5
The presence of alpha-catenin in the VE-cadherin complex is required for efficient transendothelial migration of leukocytes.α-连环蛋白在 VE-钙黏蛋白复合物中的存在是白细胞有效穿越血管内皮迁移所必需的。
Int J Biol Sci. 2009 Nov 9;5(7):695-705. doi: 10.7150/ijbs.5.695.
6
Urocortin increased LPS-induced endothelial permeability by regulating the cadherin-catenin complex via corticotrophin-releasing hormone receptor 2.尿皮质素通过促肾上腺皮质激素释放激素受体 2 调节钙黏蛋白-连环蛋白复合物增加脂多糖诱导的内皮通透性。
J Cell Physiol. 2013 Jun;228(6):1295-303. doi: 10.1002/jcp.24286.
7
Therapeutic regulation of VE-cadherin with a novel oligonucleotide drug for diabetic eye complications using retinopathy mouse models.用一种新型寡核苷酸药物对糖尿病眼部并发症的 VE-钙黏蛋白进行治疗调节,并用视网膜病变小鼠模型进行研究。
Diabetologia. 2019 Feb;62(2):322-334. doi: 10.1007/s00125-018-4770-4. Epub 2018 Nov 15.
8
Endothelial cell SHP-2 negatively regulates neutrophil adhesion and promotes transmigration by enhancing ICAM-1-VE-cadherin interaction.内皮细胞中的SHP-2通过增强ICAM-1与VE-钙黏蛋白的相互作用,对中性粒细胞黏附起负向调节作用,并促进其迁移。
FASEB J. 2017 Nov;31(11):4759-4769. doi: 10.1096/fj.201700280R. Epub 2017 Jul 12.
9
VE-cadherin and beta-catenin binding dynamics during histamine-induced endothelial hyperpermeability.组胺诱导内皮细胞高通透性过程中血管内皮钙黏蛋白和β-连环蛋白的结合动力学
Am J Physiol Cell Physiol. 2008 Apr;294(4):C977-84. doi: 10.1152/ajpcell.90607.2007. Epub 2008 Feb 20.
10
M3 muscarinic acetylcholine receptor dysfunction inhibits Rac1 activity and disrupts VE-cadherin/β-catenin and actin cytoskeleton interaction.M3 毒蕈碱型乙酰胆碱受体功能障碍抑制 Rac1 活性,破坏 VE-钙黏蛋白/β-连环蛋白和肌动蛋白细胞骨架相互作用。
Biochem Cell Biol. 2014 Apr;92(2):137-44. doi: 10.1139/bcb-2013-0042. Epub 2014 Jan 8.

引用本文的文献

1
The role of SH3RF2 in lung squamous cell carcinoma and M2 polarization: insights into LZTS2 ubiquitination.SH3RF2在肺鳞状细胞癌和M2极化中的作用:对LZTS2泛素化的见解
Biol Direct. 2025 Jul 17;20(1):87. doi: 10.1186/s13062-025-00677-0.
2
CMTM3 regulates vascular endothelial cell dysfunction by influencing pulmonary vascular endothelial permeability and inflammation in ARDS.CMTM3通过影响急性呼吸窘迫综合征(ARDS)中的肺血管内皮通透性和炎症反应来调节血管内皮细胞功能障碍。
Front Immunol. 2025 Mar 24;16:1544610. doi: 10.3389/fimmu.2025.1544610. eCollection 2025.
3
Hydrostatic pressure drives sprouting angiogenesis via adherens junction remodelling and YAP signalling.
静水压通过黏着连接重塑和 YAP 信号传导驱动出芽型血管生成。
Commun Biol. 2024 Aug 3;7(1):940. doi: 10.1038/s42003-024-06604-9.
4
Targeting PKM2 signaling cascade with salvianic acid A normalizes tumor blood vessels to facilitate chemotherapeutic drug delivery.用丹酚酸A靶向丙酮酸激酶M2信号级联可使肿瘤血管正常化,以促进化疗药物递送。
Acta Pharm Sin B. 2024 May;14(5):2077-2096. doi: 10.1016/j.apsb.2024.02.003. Epub 2024 Feb 23.
5
Motility and tumor infiltration are key aspects of invariant natural killer T cell anti-tumor function.运动性和肿瘤浸润是不变自然杀伤 T 细胞抗肿瘤功能的关键方面。
Nat Commun. 2024 Feb 9;15(1):1213. doi: 10.1038/s41467-024-45208-z.
6
T-cell infiltration and its regulatory mechanisms in cancers: insights at single-cell resolution.T 细胞浸润及其在癌症中的调控机制:单细胞分辨率的见解。
J Exp Clin Cancer Res. 2024 Feb 2;43(1):38. doi: 10.1186/s13046-024-02960-w.
7
Emerging Strategies for Immunotherapy of Solid Tumors Using Lipid-Based Nanoparticles.利用基于脂质的纳米颗粒进行实体瘤免疫治疗的新兴策略。
Adv Sci (Weinh). 2024 Feb;11(8):e2305769. doi: 10.1002/advs.202305769. Epub 2023 Dec 6.
8
Novel miRNA-based drug CD5-2 reduces liver tumor growth in diethylnitrosamine-treated mice by normalizing tumor vasculature and altering immune infiltrate.新型 miRNA 药物 CD5-2 通过使肿瘤血管正常化和改变免疫浸润来减少二乙基亚硝胺处理的小鼠肝肿瘤生长。
Front Immunol. 2023 Sep 18;14:1245708. doi: 10.3389/fimmu.2023.1245708. eCollection 2023.
9
An iRGD-conjugated photothermal therapy-responsive gold nanoparticle system carrying siCDK7 induces necroptosis and immunotherapeutic responses in lung adenocarcinoma.一种携带siCDK7的整合素靶向肽(iRGD)偶联的光热治疗响应性金纳米颗粒系统可诱导肺腺癌发生坏死性凋亡和免疫治疗反应。
Bioeng Transl Med. 2022 Oct 27;8(4):e10430. doi: 10.1002/btm2.10430. eCollection 2023 Jul.
10
Vessels that encapsulate tumour clusters vascular pattern in hepatocellular carcinoma.包裹肿瘤簇的血管在肝细胞癌中的血管模式。
JHEP Rep. 2023 May 11;5(8):100792. doi: 10.1016/j.jhepr.2023.100792. eCollection 2023 Aug.